Biocon Biologics partners with NCSM to launch Cancer Patient Assistance Program in Malaysia
By Aman Shukla Published on June 24, 2025, 08:56 IST
Biocon Biologics Limited, a global biosimilars company and a subsidiary of Biocon Ltd., has joined hands with the National Cancer Society of Malaysia (NCSM) to launch a new Patient Assistance Program (PAP). This initiative aims to improve access to affordable, high-quality cancer treatments for underserved patients in Malaysia.
Through this partnership, Biocon Biologics will supply biosimilar medicines from its oncology portfolio, including Trastuzumab, Pegfilgrastim, and Bevacizumab, to support cancer treatment in the country. The program will be managed by NCSM, which will oversee patient enrollment and the distribution of medicines as part of its broader healthcare services.
The initiative will begin with the distribution of bTrastuzumab to breast cancer patients who are currently facing treatment delays due to budget limitations.
The Memorandum of Understanding (MoU) was officially signed during the National Cancer Congress Malaysia 2025 , underscoring both organizations' commitment to advancing patient-centric healthcare and strengthening cancer care infrastructure in Malaysia.
Biocon Biologics brings its global expertise in biosimilars to the partnership, while NCSM contributes its extensive experience in community outreach and patient support. Together, they aim to reduce the treatment burden for patients and make life-saving therapies more accessible.
This program builds on Biocon Biologics' earlier success in Malaysia, where it provided insulin therapy and support to over 345,000 diabetes patients. The company is now extending its focus to oncology, using strategic collaborations to expand its impact on public health.
Ahmedabad Plane Crash
Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at BusinessUpturn.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
10 hours ago
- Business Upturn
CarTrade Tech launches ‘CarTrade Labs' to drive tech innovation
CarTrade Tech Limited has introduced CarTrade Labs , a dedicated technology and innovation unit aimed at developing next-generation solutions using generative AI, data science, and rapid prototyping. The lab will support product development across CarTrade Tech's platforms, including CarWale, BikeWale, OLX India, and Shriram Automall. Focus areas include AI-based dealer management systems, pricing tools, customer support automation, and digital retail experiences tailored to automotive buyers and sellers. CarTrade Labs is structured as an independent unit within the company and will consist of a multidisciplinary team of product professionals, engineers, and data scientists. The lab will work in close coordination with CarTrade Tech's business units to ensure real-world relevance and measurable outcomes. In addition to internal projects, the lab will seek partnerships with startups, academic bodies, and global tech providers to explore practical applications of emerging technologies. Varun Sanghi, President, CarTrade Tech, stated, 'With CarTrade Labs, we're laying the foundation for the next decade of innovation in mobility and commerce. It's a platform to reimagine, build, and scale world-class technology that creates real impact for consumers, dealers, and the ecosystem. It will give us the edge to continuously reinvent ourselves, build transformative products, and stay at the forefront of the industry.' This move reflects CarTrade Tech's broader strategy to invest in scalable tech capabilities to support its digital automotive commerce ecosystem. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Medscape
11 hours ago
- Medscape
Metastatic Breast Cancer Highlights From ASCO 2025
An exceptional range of practice-changing advancements in metastatic breast cancer across all subtypes were presented at ASCO 2025 and are discussed by Dr Ann Partridge of the Dana-Farber Cancer Institute. Beginning with HER2-positive disease, Dr Partridge reports on the DESTINY-Breast09 trial investigating whether trastuzumab deruxtecan (T-DXd) + pertuzumab (P) could improve upon results from the standard of care regimen, taxane + trastuzumab + P (THP), in the first-line setting. T-DXd + P increased progression-free survival (PFS), offering a future option for patients with very aggressive disease — although, Dr Partridge notes, several clinical questions remain. She highlights three studies in HER2-negative disease, starting with the SERENA-6 trial in which some patients treated with endocrine therapy who had ESR1 mutation, detected by circulating tumor DNA analysis, were switched to camizestrant. The camizestrant arm demonstrated meaningful PFS improvement. She also notes the first phase 3 trial of a proteolysis-targeting chimera, vepdegestrant, which demonstrated improved PFS in patients with ESR1 mutation. Continuing in the HER2-negative setting, she reports the updated overall survival results for inavolisib that continue to demonstrate positive PFS results. Switching gears to triple-negative disease, she discusses promising results from the ASCENT-04 trial, which tested the antibody-drug conjugate sacituzumab govitecan against chemotherapy.
Business Upturn
13 hours ago
- Business Upturn
Aurobindo Pharma's CuraTeQ secures UK's MHRA approval for Dyrupeg
By Aman Shukla Published on June 24, 2025, 16:58 IST CuraTeQ Biologics s.r.o., a wholly owned step-down subsidiary of Aurobindo Pharma Ltd, has received marketing authorization from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for Dyrupeg™ , a biosimilar of pegylated filgrastim. This marks the company's third biosimilar approval in the UK, following Bevqolva™ in December 2024 and Zefylti™ in May 2025. The latest approval adds to Dyrupeg's regulatory success, as it had already secured a marketing nod from the European Commission (EC) in April 2025. Pegylated filgrastim is commonly used to reduce infection risk in cancer patients undergoing chemotherapy, and the launch of Dyrupeg™ is expected to enhance patient access to affordable biologic therapies across Europe and the UK. In the exchange filing, the compamy shared, 'CuraTeQ Biologics s.r.o., a wholly owned step-down subsidiary of Aurobindo Pharma Ltd, has obtained marketing authorization from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for Dyrupeg™, its pegylated filgrastim biosimilar version. Earlier in April 2025, Dyrupeg™ received marketing authorization in the European Union from the European Commission (EC). This is CuraTeQ's third biosimilar to be approved by MHRA after the approval of Bevqolva™ in December 2024 and Zefylti™ in May 2025.' With this milestone, CuraTeQ continues to strengthen its biosimilar portfolio and expand its footprint in the global biopharmaceutical market. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
